The Ohio Department of Mental Health and Addiction Services is providing access to Pear Therapeutics’ prescription digital therapeutics reSET and reSET-O for the treatment of substance use disorder and opioid use disorder, respectively. The program is being funded by a State Opioid Response (SOR) 2.0 grant, which is administered by OhioMHAS and part of SAMHSA’s SOR grant program for individuals in need of prevention, treatment and recovery support for OUD.
Ohio marks the third state in which Pear has been awarded an SOR grant in 2021, following Indiana and Kentucky. Its digital therapeutics—reSET and reSET-O will be available to participating providers in outpatient treatment settings, including programs that offer buprenorphine.
The Pear digital therapeutics are used in conjunction with outpatient counseling to provide patients with cognitive behavioral therapy, fluency training and contingency management. The therapeutics also provide clinicians with patient data to inform in-office and telehealth-based visits. reSET is designed for patients at least 18 years of age to be used as a monotherapy for substance use disorder. reSET-O is used in combination with transmucosal buprenorphine for OUD patients at least 18 years of age.
“While the pandemic has rightfully been front and center in everyone’s minds, the opioid epidemic hasn’t gone away – it persists as a threat to our citizens and our communities,” OhioMHAS Director Lori Criss said in a news release. “This funding will help partners like Pear Therapeutics connect even more Ohioans to treatment and recovery services and support their use of new technology and innovation to stem the tide of addiction.”